Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Oktober 2014

Planlagt Fastgjort Låst Flyttet Genmab
1.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • J Offline
    J Offline
    JKY_VH
    wrote on sidst redigeret af
    #664

    Det er bare mig der er kommet hjem fra ferie:-)

    1 Reply Last reply
    0
    • C Offline
      C Offline
      cpi
      wrote on sidst redigeret af
      #665

      tja, det luk i us bliver vi vist ikke klogere af, hælder mest til, vi skal ned på mandag, måske en 3-5 kr.

      1 Reply Last reply
      0
      • SolsenS Offline
        SolsenS Offline
        Solsen
        wrote on sidst redigeret af
        #666

        Jeg synes den er helt umulig at spå om...

        1 Reply Last reply
        0
        • investor1989I Offline
          investor1989I Offline
          investor1989
          wrote on sidst redigeret af
          #667

          Revlimid det 10 dyreste lægemiddel pr. patient i verden: http://www.fiercepharma.com/special-reports/top-10-most-expensive-drugs-2013 Alexions lægemiddel klart dyrest

          1 Reply Last reply
          0
          • BudweisB Offline
            BudweisB Offline
            Budweis
            wrote on sidst redigeret af
            #668

            Dette interview William R. Strohl (VP hos Janssen) er ret interessant - http://www.bizjournals.com/philadelphia/blog/health-care/2014/08/why-the-next-big-biologic-may-be-found-by-montco.h
            tml

            1 Reply Last reply
            0
            • BudweisB Offline
              BudweisB Offline
              Budweis
              wrote on sidst redigeret af
              #669

              Just a moment...

              favicon

              (www.bizjournals.com)

              1 Reply Last reply
              0
              • BudweisB Offline
                BudweisB Offline
                Budweis
                wrote on sidst redigeret af
                #670

                Strohl said one of the difficulties in developing bispecific antibodies is overcoming manufacturing hurdles. “Most can’t be manufactured,” he said. “I have to say we were a little frustrated that we couldn’t develop, internally, a technology that could be trusted to be manufacturable.”

                Genmab’s technology proved to be the most promising solution. “We now have 20 bispecific licenses with them,” Strohl said.

                1 Reply Last reply
                0
                • J Offline
                  J Offline
                  JKY_VH
                  wrote on sidst redigeret af
                  #671

                  Tak for info Budweis.

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #672

                    Ja meget opmuntrende læsning. Kunne Janssen så ikke lige også nappe en aftale på hexabody.

                    1 Reply Last reply
                    0
                    • G Offline
                      G Offline
                      gentogen
                      wrote on sidst redigeret af
                      #673

                      Open Monoclonal Technology, Inc. (OMT), an innovator of novel genetic engineering of animals for creation of human therapeutic antibodies, today announced an alliance with Genmab A/S (OMX: GEN), a biotechnology company specializing in human antibody therapeutics. The deal gives Genmab unlimited access to OMT’s three OmniAb™ platforms, OmniRat®, OmniMouse® and OmniFlic™

                      1 Reply Last reply
                      0
                      • G Offline
                        G Offline
                        gentogen
                        wrote on sidst redigeret af
                        #674

                        Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for creation of human therapeutic antibodies, naturally optimized human antibodies®, and the only company in the world with three transgenic animal platforms

                        1 Reply Last reply
                        0
                        • G Offline
                          G Offline
                          gentogen
                          wrote on sidst redigeret af
                          #675

                          OMT has granted unlimited platform access to Genmab, Genentech, Janssen, Merck KGaA, Pfizer, Roche, Symphogen

                          1 Reply Last reply
                          0
                          • investor1989I Offline
                            investor1989I Offline
                            investor1989
                            wrote on sidst redigeret af
                            #676

                            Genmab vil have adgang til flere antistoffer som de kan kombinere i duobody

                            1 Reply Last reply
                            0
                            • celsiusC Offline
                              celsiusC Offline
                              celsius
                              wrote on sidst redigeret af
                              #677

                              Det Europæiske Lægemiddelagentur har godkendt lægemidlet Imbruvica (ibrutinib) fra Janssen og partneren Pharmacyclics til to indikationer inden for behandling af blodkræft. Markedet skærpes nu for alvor for Genmab. Er der nogen der ønsker at kommentere på det ? I artiklen står der at Imbrutinib skulle være i fase 3 kombi med Arzerra .. har det sin rigtighed ?

                              1 Reply Last reply
                              0
                              • celsiusC Offline
                                celsiusC Offline
                                celsius
                                wrote on sidst redigeret af
                                #678

                                Citat MedWatch i dag: ”Det store Genmab-håb er, at man succesfuldt kan kombinere Arzerra med Imbruvica. I øjeblikket er den kombinationsbehandling i fase 3, efter selvsamme kombination tidligere har vist særdeles stærke data i et mindre fase 2-studie”

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Sukkeralf
                                  wrote on sidst redigeret af
                                  #679

                                  Vi er ikke i fase III her, men det har været på tegnebrættet !!

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Sukkeralf
                                    wrote on sidst redigeret af
                                    #680

                                    Man er i fase III med Zydelig - og de resultater ser vi vel på ASH

                                    1 Reply Last reply
                                    0
                                    • celsiusC Offline
                                      celsiusC Offline
                                      celsius
                                      wrote on sidst redigeret af
                                      #681

                                      tak Sukker ..det mente jeg nok at kunne huske.. er Medwatch er gal på den eller læser jeg bare artiklen forkert ?

                                      1 Reply Last reply
                                      0
                                      • investor1989I Offline
                                        investor1989I Offline
                                        investor1989
                                        wrote on sidst redigeret af
                                        #682

                                        Jeg kan ikke lide hvis anonyme skal til at sælge ud flere dage i træk

                                        1 Reply Last reply
                                        0
                                        • investor1989I Offline
                                          investor1989I Offline
                                          investor1989
                                          wrote on sidst redigeret af
                                          #683

                                          medwatch er gal på den. De har skrevet det 4-5 gange nu. kan være man burde gøre dem opmærksom på det

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger